- Home
- KEP vs ITCI Comparison
KEP vs ITCI Comparison
Compare KEP & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEP
- ITCI
- Stock Information
- Founded
- KEP 1961
- ITCI 2002
- Country
- KEP South Korea
- ITCI United States
- Employees
- KEP N/A
- ITCI N/A
- Industry
- KEP Electric Utilities: Central
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- KEP Utilities
- ITCI Health Care
- Exchange
- KEP Nasdaq
- ITCI Nasdaq
- Market Cap
- KEP 9.4B
- ITCI 8.0B
- IPO Year
- KEP N/A
- ITCI N/A
- Fundamental
- Price
- KEP $8.18
- ITCI $83.42
- Analyst Decision
- KEP
- ITCI Strong Buy
- Analyst Count
- KEP 0
- ITCI 12
- Target Price
- KEP N/A
- ITCI $97.67
- AVG Volume (30 Days)
- KEP 87.7K
- ITCI 733.0K
- Earning Date
- KEP 12-01-2024
- ITCI 10-30-2024
- Dividend Yield
- KEP N/A
- ITCI N/A
- EPS Growth
- KEP N/A
- ITCI N/A
- EPS
- KEP 4.40
- ITCI N/A
- Revenue
- KEP $70,353,869,926.00
- ITCI $613,728,000.00
- Revenue This Year
- KEP $5.44
- ITCI $48.25
- Revenue Next Year
- KEP $3.10
- ITCI $38.47
- P/E Ratio
- KEP $3.68
- ITCI N/A
- Revenue Growth
- KEP 8.48
- ITCI 46.08
- 52 Week Low
- KEP $6.69
- ITCI $54.17
- 52 Week High
- KEP $9.55
- ITCI $93.45
- Technical
- Relative Strength Index (RSI)
- KEP 54.90
- ITCI 50.72
- Support Level
- KEP $7.58
- ITCI $89.28
- Resistance Level
- KEP $8.30
- ITCI $93.45
- Average True Range (ATR)
- KEP 0.10
- ITCI 3.23
- MACD
- KEP -0.02
- ITCI -0.27
- Stochastic Oscillator
- KEP 74.07
- ITCI 43.90
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.